



Centre for
Public Health

Merseyside Inter Agency Drug Misuse Database

January– March 2007

Liverpool DAAT

Quarter 4 2006/07

**Esther Shepherd, Martin Chandler,
Jim McVeigh**

DRAFT REPORT

The final version will be available on the IAD website

www.cph.org.uk/iad

Acknowledgements:

The Authors would like to thank the following for their valuable contributions to the production of this report: Paul Duffy, Adam Marr, Simon Russell and Claire Shaw.

We would also like to thank the data providers for their efforts in assisting and maintaining the monitoring process.

Contacts:

Martin Chandler
IAD Manager
Centre for Public Health
Faculty of Health & Applied Social Sciences
Liverpool John Moores University
Castle House
North Street
L3 2AY

(0151) 231 4531
m.chandler@ljmu.ac.uk

Esther Shepherd
IAD Researcher

(0151) 231 4521
e.shepherd@ljmu.ac.uk

www.cph.org.uk/iad

Contents

	<u>Page</u>
Introduction	1
Arrest Referral	3
Table 1: Individuals assessed, by Gender and Age Group	
Table 2: Year to Date, by Gender and Age Group	
Table 3: Reported Main Drug(s) of Use, by Frequency of Use	
Probation	5
Syringe Exchange Services	6
Agency	
Table 4: Individuals by Gender	
Table 5: Individuals by Gender: Steroid Users omitted	
Table 6: Individuals by Age Group	
Table 7: Individuals by Age Group: Steroid Users omitted	
Table 8: Gender by Age Group of Individuals	
Table 9: Gender by Age Group: Steroid Users omitted	
Table 10: Year to Date, by Gender & Age Group	
Table 11: Year to Date, by Gender & Age Group: Steroid Users omitted	
Table 12: Main Drug of Use for New Agency Syringe Exchange Clients, by Gender	
Table 13: Main Drug of Use, for New Agency Syringe Exchange Clients, by Age Group	
Pharmacy	11
Table 14: Individuals by Gender	
Table 15: Individuals by Age Group	
Table 16: Year to Date, by Gender & Age Group	
Combined	12
Table 17: Individuals in Syringe Exchange, by Gender	
Table 18: Individuals in Syringe Exchange, by Gender: Steroid Users omitted	
Table 19: Individuals in Syringe Exchange, by Age Group	
Table 20: Individuals in Syringe Exchange, by Age Group: Steroid Users omitted	
Table 21: Year to Date, by Gender & Age Group	
Table 22: Total Syringes Provided	

National Drug Treatment Monitoring System (NDTMS) 14

Table 23: Individuals in contact with Treatment Services, by Gender

Table 24: Year to Date, by Gender

Table 25: Individuals in contact with Treatment Services, by Age Group

Table 26: Year to Date, by Age Group

Table 27: Ethnicity of Individuals in Contact with Treatment Services

Table 28: Individuals in contact with Treatment Services, by Main Drug of Use

Connexions 17

Table 29: Individuals in Contact with Connexions, by Gender

Table 30: Year to Date, by Gender

Table 31: Individuals in Contact with Connexions, by Age

Table 32: Year to Date, by Age

Table 33: Individuals in Contact with Connexions by Drug/Alcohol Problem

Table 34: Year to Date, by Drug/Alcohol Problem

Combined Datasets 19

Table 35: Total Problem Drug Users reported to the IAD, by Gender and Age Group

Table 36: Year to Date, by Gender & Age Group

Cross Matched Datasets 20

Fig 1: Crossover between Agency Syringe Exchange and NDTMS datasets

Fig 2: Crossover between Pharmacy Syringe Exchange and NDTMS datasets

Introduction

The Inter Agency Drug Misuse Database (IAD), established by Merseyside Drug (and Alcohol) Action Teams, Merseyside Police and the Public Health Sector (now Centre for Public Health) in 1997, supports the need for local information on drug misuse. In particular the IAD aims to:

- Provide comprehensive reporting of problem drug users' (PDUs') characteristics including a range of demographics and the types of drugs used.
- Reflect levels of service and intervention activity.
- Assist in D(A)AT's (and other responsible bodies) performance management.
- Facilitate the planning and development of services and interventions for PDUs.
- Identify gaps in service provision and delivery, as well as under-served groups as specified by the National Treatment Agency and Department of Health and by the Centre for Public Health, through interrogation of available data.
- Highlight changes in levels, demographics and characteristics of drug user populations.
- Report back to both individual D(A)ATs and service providers in the form of audits and quarterly reports as well as responding to ad hoc requests.
- Provide summary reporting on an annual basis.


To enable the above the IAD collects data from as many agencies in contact with drug users as possible and is continually seeking to expand the range and scope of data providers. Data are currently collected from criminal justice services, needle exchange schemes (both pharmacy and agency-based), the National Drug Treatment Monitoring System (NDTMS) and Connexions (young people).

Data considerations

Analysis of data depends on the provision of attributable information. Each service provider records first and last initials, date of birth and gender, for each individual they record a contact with. The combination of these details provides an identifier (attributor) for each individual (e.g.: HF07/12/1974M). This is a nationally recognised system and allows individuals to be tracked through different service providers and across time whilst retaining an acceptable degree of anonymity. The attributor is essential to avoid double counting of individuals both within and across datasets, as well as enabling us to match across datasets. The D(A)AT referred to is the D(A)AT of contact unless otherwise stated.

The IAD will *only* be reporting attributable data for each dataset. In the past, report deadlines have been missed due to data arriving too late to be cleaned and analysed in time, or more often because the data requires a great deal of cleaning and validation before analysis. These reports are useful only if they can arrive within timelines useful to D(A)ATs (ie: in time for NTA quarterly submissions). For this reason, reports will now be sent out according to a strict timetable, with each quarter's report to be sent in the first week of the third month following the close of the reporting period. Any data that is missing or non-attributable will not be included in the report.

Year-to-Date figures will be provided for the current financial year, and will incorporate updated figures from previous quarters. The figures are calculated by aggregating successive quarterly datasets to omit double counting of those who present to services in each quarter. Year-to-Date data will be the most accurate reflection of annual service activity and will override previous quarterly data.



The Centre for Public Health will continue to work closely with service providers and D(A)ATs in order to improve both the timeliness and quality of monitoring data provided to the IAD. Many service providers are turning to electronic recording of data and it is hoped this will vastly improve the quality of the data as systems improve.

ARREST REFERRAL (AR)**Quarter 4 (2006/07)****Introduction**

Raw data are provided by the Drug Intervention Programme (DIP) Team based at the Centre for Public Health, Liverpool John Moores University. The data supplied are for validated contacts within specified D(A)AT areas and are aggregated to one person per D(A)AT area. Individuals may therefore appear more than once within the final dataset if they have been seen in more than one D(A)AT area, but only once for each D(A)AT area within the reporting period.

Table 1: Individuals assessed, by Gender & Age Group

Gender	n	%
Male	379	79.0
Female	101	21.0
Age Group		
Under 18	2	0.4
18-19	33	6.9
20-24	76	15.8
25-29	77	16.0
30-34	100	20.8
35-39	100	20.8
40-44	71	14.8
45+	21	4.4
Total	480	100

Table 2: Year to Date, by Gender & Age Group

Age Group	Gender				Total in Age Group	
	Male		Female		n	%
	n	%	n	%		
Under 18	3	0.2	1	0.3	4	0.3
18-19	92	7.5	16	4.6	108	6.9
20-24	200	16.3	41	11.8	241	15.3
25-29	191	15.6	56	16.1	247	15.7
30-34	262	21.3	76	21.9	338	21.5
35-39	236	19.2	86	24.8	322	20.4
40-44	166	13.5	53	15.3	219	13.9
45+	78	6.4	18	5.2	96	6.1
Total	1228	100	347	100	1575	100

Table 3: Reported Main Drug(s) of Use, by Frequency of Use

Drug of Use	Daily	Weekly
Amphetamines	5	1
Benzodiazepines	18	5
Cannabis	48	8
Crack	203	39
Cocaine	25	68
Ecstasy	0	3
Heroin	244	32
Methadone	43	3
Other	3	1

NB: The complexity of the drug profiles reported through arrest referral is such that we have decided the best way of reporting the data is to provide figures for the number of people reporting Daily or Weekly use of each drug. Where “Main drug” is provided in the original data it does not always match the other substances reported as being used daily; consequently, this method of reporting should provide a more accurate picture of drug use as reported through Arrest Referral rather than simply stating the “Main Drug”. However it should be noted that some people may report several drugs being used and will therefore be counted in the figures for each drug they report. For this reason totals are not provided.

PROBATION

Quarter 4 (2006/07)

Introduction

Due to last minute technical problems it was not possible to include Probation data for this quarter. The Annual Report will however, include data from Quarter 4 2006/07.

SYRINGE EXCHANGE SERVICES

Quarter 4 (2006/07)

Introduction

Data are collected directly from syringe exchange providers. Analysis of syringe exchange data allows performance monitoring of harm reduction services at both D(A)AT and service provider level.

AGENCY SYRINGE EXCHANGE

Table 4: Individuals by Gender

New Clients	n	%
Male	84	87.5
Female	12	12.5
<i>Total</i>	96	100
All Clients		
Male	431	88.3
Female	57	11.7
<i>Total</i>	488	100

Table 5: Individuals by Gender: Steroids Users Omitted

New Clients	n	%
Male	42	77.8
Female	12	22.2
<i>Total</i>	54	100
All Clients		
Male	285	83.3
Female	57	16.7
<i>Total</i>	342	100

Table 6: Individuals by Age Group

Age Group	New Clients		All Clients	
	n	%	n	%
Under 18	0	0	0	0
18-19	3	3.1	3	0.6
20-24	15	15.6	49	10.0
25-29	22	22.9	89	18.2
30-34	17	17.7	93	19.1
35-39	18	18.8	122	25.0
40-44	17	17.7	89	18.2
45+	4	4.2	43	8.8
Total	96	100	488	100

Table 7: Individuals by Age Group: Steroid Users Omitted

Age Group	New Clients		All Clients	
	n	%	n	%
Under 18	0	0	0	0
18-19	1	1.9	1	0.3
20-24	1	1.9	9	2.6
25-29	8	14.8	45	13.2
30-34	11	20.4	70	20.5
35-39	15	27.8	103	30.1
40-44	16	29.6	79	23.1
45+	2	3.7	35	10.2
Total	54	100	342	100

Table 8: Gender by Age Group of Individuals

	Gender			
	Male		Female	
Age Group	n	%	n	%
Under 18	0	0	0	0
18-19	3	0.7	0	0
20-24	45	10.4	4	7.0
25-29	79	18.3	10	17.5
30-34	84	19.5	9	15.8
35-39	105	24.4	17	29.8
40-44	75	17.4	14	24.6
45+	40	9.3	3	5.3
Total	431	100	57	100

Table 9: Gender by Age Group: Steroid Users omitted

	Gender			
	Male		Female	
Age Group	n	%	n	%
Under 18	0	0	0	0
18-19	1	0.4	0	0
20-24	5	1.8	4	7.0
25-29	35	12.3	10	17.5
30-34	61	21.4	9	15.8
35-39	86	30.2	17	29.8
40-44	65	22.8	14	24.6
45+	32	11.2	3	5.3
Total	285	100	57	100

Table 10: Year to Date, by Gender & Age Group

Age Group	Gender				Total in Age Group	
	Male		Female		n	%
	n	%	n	%		
Under 18	0	0	1	0.7	1	0.1
18-19	18	1.8	2	1.4	20	1.8
20-24	127	12.8	11	7.6	138	12.1
25-29	192	19.3	21	14.6	213	18.7
30-34	218	22.0	40	27.8	258	22.7
35-39	227	22.9	36	25.0	263	23.1
40-44	132	13.3	24	16.7	156	13.7
45+	79	8.0	9	6.3	88	7.7
Total	993	100	144	100	1137	100

Table 11: Year to Date, by Gender & Age Group: Steroid Users Omitted

Age Group	Gender				Total in Age Group	
	Male		Female		n	%
	n	%	n	%		
Under 18	0	0	1	0.7	1	0.1
18-19	4	0.6	2	1.4	6	0.8
20-24	29	4.7	11	7.6	40	5.2
25-29	78	12.6	21	14.6	99	13.0
30-34	153	24.7	40	27.8	193	25.3
35-39	183	29.5	36	25.0	219	28.7
40-44	110	17.7	24	16.7	134	17.5
45+	63	10.2	9	6.3	72	9.4
Total	620	100	144	100	764	100

Table 12: Main Drug of Use for New Agency Syringe Exchange Clients, by Gender

Drug of Use	Gender			
	Male		Female	
	n	%	n	%
Amphetamines	0	0	1	8.3
Cocaine	1	1.2	0	0
Crack	1	1.2	2	16.7
Heroin	36	42.9	8	66.7
Steroids	42	50.0	0	0
Unknown	4	4.8	1	8.3
Total	84	100	12	100

Please Note: Due to changes in reporting methods we will now only report drug of use for new clients. Information on drug of use for all clients is available on request.

Table 13: Main Drug of Use for New Agency Syringe Exchange Clients, by Age Group

Age Group	Ampheta- mine		Cocaine		Crack		Heroin		Steroids		Unknown	
	n	%	n	%	n	%	n	%	n	%	n	%
Under 18	0	0	0	0	0	0	0	0	0	0	0	0
18-19	0	0	0	0	0	0	0	0	2	66.7	1	33.3
20-24	0	0	0	0	0	0	1	6.7	14	93.3	0	0
25-29	0	0	0	0	1	4.5	5	22.7	14	63.6	2	9.1
30-34	0	0	0	0	0	0	11	64.7	6	35.3	0	0
35-39	0	0	0	0	0	0	14	77.8	3	16.7	1	5.6
40-44	1	5.9	1	5.9	2	11.8	12	70.6	1	5.9	0	0
45+	0	0	0	0	0	0	1	25.0	2	50.0	1	25.0
Total*	1	1.0	1	1.0	3	3.1	44	45.8	42	43.8	5	5.2

* % Totals are by Drug, not Age Group

PHARMACY SYRINGE EXCHANGE

Table 14: Individuals by Gender

New Clients	n	%
Male	306	88.7
Female	39	11.3
<i>Total</i>	<i>345</i>	<i>100</i>
All Clients		
Male	812	82.9
Female	167	17.1
<i>Total</i>	<i>979</i>	<i>100</i>

Table 15: Individuals by Age Group

Age Group	New Clients		All Clients	
	n	%	n	%
Under 18	2	0.6	3	0.3
18-19	10	2.9	22	2.2
20-24	45	13.0	82	8.4
25-29	47	13.6	104	10.6
30-34	69	20.0	195	19.9
35-39	81	23.5	297	30.3
40-44	61	17.7	187	19.1
45+	30	8.7	89	9.1
<i>Total</i>	<i>345</i>	<i>100</i>	<i>979</i>	<i>100</i>

Table 16: Year to Date, by Gender & Age Group

Age Group	Gender				<i>Total in Age Group</i>	
	Male		Female			
	n	%	n	%	<i>n</i>	<i>%</i>
Under 18	14	0.7	2	0.4	<i>16</i>	<i>0.6</i>
18-19	62	3.0	9	2.0	<i>71</i>	<i>2.8</i>
20-24	220	10.5	17	3.8	<i>237</i>	<i>9.3</i>
25-29	250	12.0	60	13.3	<i>310</i>	<i>12.2</i>
30-34	426	20.4	110	24.4	<i>536</i>	<i>21.1</i>
35-39	547	26.2	129	28.7	<i>676</i>	<i>26.6</i>
40-44	390	18.7	81	18.0	<i>471</i>	<i>18.6</i>
45+	180	8.6	42	9.3	<i>222</i>	<i>8.7</i>
<i>Total</i>	<i>2089</i>	<i>100</i>	<i>450</i>	<i>100</i>	<i>2539</i>	<i>100</i>

COMBINED PHARMACY AND AGENCY SYRINGE EXCHANGE

Analyses here are based on an aggregated combination of Agency and Pharmacy-based datasets for the reporting period. Data are aggregated by attributor and D(A)AT to one person per D(A)AT area.

Table 17: Individuals in Syringe Exchange, by Gender

New Clients	n	%
Male	386	88.3
Female	51	11.7
<i>Total</i>	<i>437</i>	<i>100</i>
All Clients		
Male	1172	84.9
Female	209	15.1
Total	1381	100

Table 18: Individuals in Syringe Exchange, by Gender: Steroid Users Omitted

New Clients	n	%
Male	51	76.1
Female	16	23.9
<i>Total</i>	<i>67</i>	<i>100</i>
All Clients		
Male	1026	83.9
Female	209	16.9
Total	1235	100

Table 19: Individuals in Syringe Exchange, by Age Group

Age Group	New Clients		All Clients	
	n	%	n	%
Under 18	2	0.5	3	0.2
18-19	13	3.0	25	1.8
20-24	60	13.7	128	9.3
25-29	67	15.3	183	13.3
30-34	86	19.7	268	19.4
35-39	98	22.4	390	28.2
40-44	77	17.6	260	18.8
45+	34	7.8	124	9.0
Total	437	100	1381	100

Table 20: Individuals in Syringe Exchange by Age Group: Steroid Users Omitted

Age Group	New Clients		All Clients	
	n	%	n	%
Under 18	0	0	3	0.2
18-19	1	1.5	23	1.9
20-24	2	3.0	88	7.1
25-29	11	16.4	139	11.3
30-34	16	23.9	245	19.8
35-39	17	25.4	371	30.0
40-44	18	26.9	250	20.2
45+	2	3.0	116	9.4
Total	67	100	1235	100

Table 21: Year to Date, by Gender & Age Group

Age Group	Gender				Total in Age Group	
	Male		Female			
	n	%	n	%	n	%
Under 18	14	0.5	2	0.4	16	0.5
18-19	78	2.7	11	2.0	89	2.6
20-24	335	11.7	25	4.6	360	10.6
25-29	425	14.9	78	14.3	503	14.8
30-34	578	20.3	135	24.7	713	21.0
35-39	699	24.5	151	27.7	850	25.0
40-44	478	16.8	96	17.6	574	16.9
45+	245	8.6	48	8.8	293	8.6
Total	2852	100	546	100	3398	100

Table 22: Total Syringes Provided

	This Quarter	Year to Date
Barrels	131,149	563,843
Needles	144,582	621,095

NB: We will no longer be reporting needle returns as it is not possible to accurately calculate them from the data available. Total Syringes include exchanges by non-attributable individuals.

National Drug Treatment Monitoring System (NDTMS)

Quarter 4 (2006/07)

Background

The NDTMS is the official method for measuring the extent and nature of structured drug treatment in England and Wales. The system is commissioned by the NTA and is operated through nine regional centres – corresponding to the nine government offices for the regions.

Data here are aggregated to one individual per D(A)AT. Individuals presenting in more than one D(A)AT within the quarter's time period will therefore be represented more than once in the original data. The D(A)AT referred to is D(A)AT of treatment.

New Clients

Figures presented here for "new" clients are calculated using the triage date. Those individuals triaged within the reporting period are taken as new clients for this report. However, it should be noted that these individuals may have been triaged, or in contact with treatment services, before this period.

Table 23: Individuals in Contact with Treatment Services, by Gender

New Clients	n	%
Male	409	75.6
Female	132	24.4
<i>Total</i>	<i>541</i>	<i>100</i>
All Clients		
Male	2,798	68.8
Female	1,267	31.2
<i>Total</i>	<i>4,065</i>	<i>100</i>

Table 24: Year to Date, by Gender

New Clients	n	%
Male	1517	71.4
Female	607	28.6
<i>Total</i>	<i>2124</i>	<i>100</i>
All Clients		
Male	3322	69.3
Female	1471	30.7
<i>Total</i>	<i>4793</i>	<i>100</i>

Table 25: Individuals in Contact with Treatment Services, by Age Group

Age Group	New Clients		All Clients	
	n	%	n	%
Under 18	32	5.9	165	4.1
18-19	13	2.4	57	1.4
20-24	24	4.4	145	3.6
25-29	61	11.3	347	8.5
30-34	117	21.6	742	18.3
35-39	140	25.9	1,134	27.9
40-44	95	17.6	925	22.8
45+	59	10.9	550	13.5
Total	541	100	4,065	100

Table 26: Year to Date, by Age Group

Age Group	New Clients		All Clients	
	n	%	n	%
Under 18	174	8.2	206	4.3
18-19	35	1.6	73	1.5
20-24	132	6.2	337	7.0
25-29	249	11.7	603	12.6
30-34	475	22.4	1130	23.6
35-39	512	24.1	1302	27.2
40-44	363	17.1	723	15.1
45+	184	8.7	419	8.7
Total	2124	100	4,793	100

Table 27: Ethnicity of Individuals in Contact with Treatment Services

Ethnicity	New Clients		All Clients	
	n	%	n	%
White British	500	92.4	3,780	92.3
White Irish	5	0.9	29	0.7
Other White	3	0.6	35	0.9
White & Black Caribbean	5	0.9	13	0.3
White & Black African	1	0.2	2	0.1
White & Asian	0	0	2	0.1
Other mixed	1	0.2	10	0.3
Indian	1	0.2	1	<0.1
Other Asian	3	0.6	8	0.2
Caribbean	1	0.2	4	0.1
African	1	0.2	6	0.2
Other Black	8	1.5	45	1.1
Chinese	1	0.2	9	0.2
Other/Unknown	11	2.0	121	3.0
<i>Total</i>	<i>541</i>	<i>100</i>	<i>4065</i>	<i>100</i>

Table 28: Individuals in Contact with Treatment Services, by Main Drug of Use

Drug of Use	New Clients		All Clients	
	n	%	n	%
Heroin	348	64.3	2,558	62.9
Methadone	25	4.6	328	8.1
Other Opiates	8	1.5	101	2.5
Benzodiazepine	3	0.6	11	0.3
Amphetamines	3	0.6	31	0.8
Cocaine	70	12.9	343	8.4
Crack	24	4.5	109	2.7
Ecstasy	4	0.7	24	0.6
Cannabis	55	10.2	287	7.1
Solvents	0	0	2	0.1
Hallucinogens	0	0	1	<0.1
Antidepressants	0	0	2	0.1
Other/Unknown	1	0.2	268	6.6
<i>Total</i>	<i>541</i>	<i>100</i>	<i>4065</i>	<i>100</i>

CONNEXIONS

Quarter 4 (2006/07)

Background

Connexions provide a support service for young people, aged 13-19. The Greater Merseyside Connexions Partnership provides data presented here.

Table 29: Individuals in Contact with Connexions, by Gender

Gender	n	%
Male	81	75.0
Female	27	25.0
Total	108	100

Table 30: Year to Date, by Gender

Gender	n	%
Male	126	75.9
Female	40	24.1
Total	166	100

Table 31: Individuals in Contact with Connexions, by Age

Age Group	n	%
16	33	30.6
17	27	25.0
18	33	30.6
19	15	13.9
Total	108	100

Table 32: Year to Date, by Age

Age Group	n	%
16	49	29.5
17	39	23.5
18	49	29.5
19	29	17.5
Total	166	100

Table 33: Individuals in Contact with Connexions by Drug/Alcohol Problem

Substance	n	%
Alcohol/Other*	19	17.6
Drugs	89	82.4
Total	108	100

*"Other" is generally used to refer to solvents although this is not necessarily always the case.

Table 34: Year to Date, by Drug/Alcohol Problem

Substance	n	%
Alcohol/Other*	35	21.1
Drugs	131	78.9
Total	166	100

*"Other" is generally used to refer to solvents although this is not necessarily always the case.

COMBINED DATASETS

Quarter 4 (2006/07)

Introduction

Data presented here are drawn from a combination of datasets relating to Arrest Referrals, Syringe Exchange (Agency and Pharmacy), NDTMS and Connexions. The combined data are aggregated on attributor and D(A)AT area of intervention, to produce overall figures for numbers of individuals in contact with services reporting to the IAD. Figures presented here will not necessarily reflect the combined totals of data presented earlier as duplicate attributors are removed. These figures should not be taken as a measure of prevalence of problem drug users, but reflects the total number of problem drug users in contact with a range of agencies. Further information on the processes of data manipulation, aggregation and analysis is available from the IAD Manager.

Table 35: Total Problem Drug Users reported to the IAD, by Gender and Age Group

Gender	n	%
Male	3989	73.1
Female	1465	26.9
Age Group		
Under 18	253	4.6
18-19	157	2.9
20-24	437	8.0
25-29	647	11.9
30-34	1136	20.8
35-39	1435	26.3
40-44	896	16.4
45+	493	9.0
Total	5454	100

Table 36: Year to Date, by Gender and Age Group

Age Group	Gender				Total in Age Group	
	Male		Female		n	%
	n	%	n	%		
Under 18	231	3.5	73	3.6	304	3.5
18-19	270	4.1	66	3.2	336	3.9
20-24	705	10.8	185	9.0	890	10.4
25-29	914	14.0	302	14.8	1216	14.2
30-34	1339	20.5	503	24.6	1842	21.5
35-39	1568	24.0	494	24.1	2062	24.0
40-44	963	14.7	274	13.4	1237	14.4
45+	548	8.4	150	7.3	698	8.1
Total	6538	100	2047	100	8585	100

CROSS-MATCHED DATASETS

Quarter 4 (2006/07)

Data are shown for the crossover between each type of Syringe Exchange and NDTMS, separately, during the current reported quarter. For the purposes of this analysis, known steroid users were removed as they are less likely to be accessing structured drug treatment.

For methodological reasons the crossover between all three datasets will no longer be reported. Further information is available from the IAD manager if required.

NB: Numbers in brackets refer to the total reported for that service type, with steroid users omitted. These include the numbers appearing on the crossover sections. Analyses for the crossover areas are based on D(A)AT of Syringe Exchange site.

Fig 1: Crossover between Agency Syringe Exchange and NDTMS datasets




Fig 2: Crossover between Pharmacy Syringe Exchange and NDTMS datasets

